Inhaled insulin (Afrezza; MannKind Corporation) continues to build a case for broader adoption in pediatric diabetes care.
After FDA approval for children 6 and older, ADA data show inhaled insulin's safety and satisfaction benefits, but clinician ...
Evidence-Based Diabetes Management | Journals | The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results